Marc van Dijk

Company: MiNK Therapeutics

Job title: Chief Scientific Officer

Seminars:

Assessing Techniques to Improve the TME For Therapeutic Discovery & Development 9:00 am

Highlighting the importance of designing tumour models that accurately represent the immune component to effectively evaluate immuno-oncology therapies  Uncovering methods for TME remodelling to promote immune activation  Implementing tumour models including CDX/PDX mice and 3D tissue model systems to assess combination therapies of cancer vaccines with checkpoint inhibitorsRead more

day: Conference Day One